Equities research firm Zacks Research recently downgraded Rhythm Pharmaceuticals (NASDAQ:RYTM) from a “hold” rating to a “strong sell” rating. This decision was outlined in a research...
Rhythm Pharmaceuticals (NASDAQ: RYTM) faced a significant downgrade from Zacks Research, moving from a “hold” rating to a “strong sell” rating, as reported on Monday. This...
